## DGX: Quest Diagnostics Incorporated - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.5% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($176.14)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Bellevue Group AG Makes New $8.72 Million Investment in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251213T093035 | Somewhat-Bullish | Relevance: 100%
- Bellevue Group AG has acquired a new stake of 48,567 shares in Quest Diagnostics Incorporated, valued at approximately $8.72 million. This investment comes as other institutional investors have also adjusted their positions in DGX, and the company has received a "Moderate Buy" consensus rating from analysts with an average price target of $197.27. Quest Diagnostics recently announced a quarterly dividend of $0.80 per share to be paid on January 28th.

**2. Looking Into Quest Diagnostics Inc's Recent Short Interest**
- Source: Sahm | 20251211T190809 | Somewhat-Bearish | Relevance: 100%
- Quest Diagnostics Inc.'s (NYSE: DGX) short interest has increased by 16.75% to 4.61 million shares, now representing 4.74% of its float. This rise suggests a more bearish sentiment among investors, though it doesn't necessarily predict a near-term stock decline. Compared to its peers, Quest Diagnostics has less short interest, with the average peer percentage being 9.92%.

**3. Bayesian Capital Management LP Takes Position in Quest Diagnostics Incorporated $DGX**
- Source: MarketBeat | 20251212T070816 | Somewhat-Bullish | Relevance: 100%
- Bayesian Capital Management LP has initiated a new position in Quest Diagnostics (NYSE:DGX), purchasing 15,700 shares valued at approximately $2.82 million. This move comes as other institutional investors have also adjusted their stakes in DGX, although company insiders have been net sellers, divesting over $17 million in shares recently. Quest Diagnostics reported strong Q3 earnings, exceeding estimates with $2.60 EPS and $2.82 billion in revenue, and has set positive FY2025 guidance.

**4. Nonalcoholic Steatohepatitis Diagnostics Market Is Going to Boom |• Exact Sciences Corporation • Genfit SA**
- Source: openPR.com | 20251215T080932 | Somewhat-Bullish | Relevance: 84%
- Worldwide Market Reports (WMR) projects substantial growth for the Nonalcoholic Steatohepatitis Diagnostics Market, offering a comprehensive analysis of market dynamics, drivers, and regional insights. The report identifies key players such as Exact Sciences Corporation and Genfit SA and segments the market by types and applications. It provides actionable intelligence and forecasts using extensive primary and secondary research.

**5. Labcorp (LH): Reassessing Valuation After Reduced Growth Outlook for Contract Research Unit**
- Source: Simply Wall Street | 20251213T185008 | Neutral | Relevance: 64%
- Labcorp Holdings (LH) recently surpassed earnings expectations but saw its stock react negatively due to management's cautious outlook, including reduced revenue growth targets for its contract research unit and a trimmed full-year forecast. Despite a strong 5-year shareholder return, the stock's recent weakness suggests investors are reassessing growth risks. Analysts currently see Labcorp as undervalued with a fair value of $299.71, though its P/E ratio is higher than the broader US healthcare sector.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 9 ($1.18M) |
| Sells | 8 ($8.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.8% (+0.1%)
- Blackrock Inc.: 9.0% (-3.0%)
- JPMORGAN CHASE & CO: 7.8% (+99.3%)
- Price (T.Rowe) Assoc: 6.3% (-2.6%)
- State Street Corpora: 4.7% (+0.8%)

### Key Risks

1. Insider selling cluster: $8.9M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +4.6% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 17.6x stretched relative to 6% growth. Insider selling cluster ($8.9M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $20.4B |
| Beta | 0.62 |
| 52W Range | $148.70 - $197.55 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 17.6 |
| Current P/E | 18.6 |
| YoY Growth | 5.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -3.1% to 1.5% (+4.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.5pp (needs >3.0% for momentum thesis). MRS_5 at 2.2% confirms short-term momentum alignment. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-0.71), momentum weakening. RSI neutral at 47. OFD pattern: +SLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.49% (CS: 46) | Neutral |
| RSI_14 | 47.3 | Neutral |
| MACD Histogram | -0.71 | Bearish |
| vs SMA20 | 0.985x | Below |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 1.031x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $182.56
- **Stop Loss:** $176.14 (3.5% risk)
- **Target:** $188.98 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 155
- **Position Value:** $28,296.80
- **Portfolio %:** 28.30%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-27 (Est: $2.36)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.60 | +3.9% |
| 2025Q2 | $2.57 | $2.62 | +1.9% |
| 2025Q1 | $2.15 | $2.21 | +2.8% |
| 2024Q4 | $2.18 | $2.23 | +2.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*